Literature DB >> 10567263

Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa.

R K Ernst1, E C Yi, L Guo, K B Lim, J L Burns, M Hackett, S I Miller.   

Abstract

Cystic fibrosis (CF) patients develop chronic airway infections with Pseudomonas aeruginosa (PA). Pseudomonas aeruginosa synthesized lipopolysaccharide (LPS) with a variety of penta- and hexa-acylated lipid A structures under different environmental conditions. CF patient PA synthesized LPS with specific lipid A structures indicating unique recognition of the CF airway environment. CF-specific lipid A forms containing palmitate and aminoarabinose were associated with resistance to cationic antimicrobial peptides and increased inflammatory responses, indicating that they are likely to be involved in airway disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567263     DOI: 10.1126/science.286.5444.1561

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  179 in total

Review 1.  The pleiotropic two-component regulatory system PhoP-PhoQ.

Authors:  E A Groisman
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

Review 2.  Lipopolysaccharide endotoxins.

Authors:  Christian R H Raetz; Chris Whitfield
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

3.  Vanadate and triclosan synergistically induce alginate production by Pseudomonas aeruginosa strain PAO1.

Authors:  F Heath Damron; Michael R Davis; T Ryan Withers; Robert K Ernst; Joanna B Goldberg; Guangli Yu; Hongwei D Yu
Journal:  Mol Microbiol       Date:  2011-06-16       Impact factor: 3.501

4.  Interaction of pseudomonas aeruginosa with epithelial cells: identification of differentially regulated genes by expression microarray analysis of human cDNAs.

Authors:  J K Ichikawa; A Norris; M G Bangera; G K Geiss; A B van 't Wout; R E Bumgarner; S Lory
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

5.  Crystal structure and catalytic mechanism of the LPS 3-O-deacylase PagL from Pseudomonas aeruginosa.

Authors:  Lucy Rutten; Jeroen Geurtsen; Wietske Lambert; Jeroen J M Smolenaers; Alexandre M Bonvin; Alex de Haan; Peter van der Ley; Maarten R Egmond; Piet Gros; Jan Tommassen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

Review 6.  Molecular basis of bacterial outer membrane permeability revisited.

Authors:  Hiroshi Nikaido
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

7.  Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.

Authors:  Robert K Ernst; Samuel M Moskowitz; Julia C Emerson; Gretchen M Kraig; Kristin N Adams; Megan D Harvey; Bonnie Ramsey; David P Speert; Jane L Burns; Samuel I Miller
Journal:  J Infect Dis       Date:  2007-08-22       Impact factor: 5.226

8.  A divergent Pseudomonas aeruginosa palmitoyltransferase essential for cystic fibrosis-specific lipid A.

Authors:  Iyarit Thaipisuttikul; Lauren E Hittle; Ramesh Chandra; Daniel Zangari; Charneal L Dixon; Teresa A Garrett; David A Rasko; Nandini Dasgupta; Samuel M Moskowitz; Lars Malmström; David R Goodlett; Samuel I Miller; Russell E Bishop; Robert K Ernst
Journal:  Mol Microbiol       Date:  2013-11-27       Impact factor: 3.501

Review 9.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity.

Authors:  Nathan E Head; Hongwei Yu
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.